NPS Pharma reiterated by Jefferies at buy

NPS Pharmaceuticals Inc. was maintained by Jefferies & Co. analyst Adam Walsh at a buy rating with a price target on the stock of $16 per share following a conference hosted by the firm featuring two osteoporosis specialists that expect a bright future for Preos and the anabolic therapies for osteoporosis. NPS Pharma shares Wednesday were down $0.02, or 0.16%, at $12.15 on volume of 964,700 shares versus the three-month running average of 483,457 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.